- Home
- CRNX vs FSK Comparison
CRNX vs FSK Comparison
Compare CRNX & FSK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CRNX | FSK |
|---|---|---|
| Founded | 2008 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 4.5B |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | CRNX | FSK |
|---|---|---|
| Price | $47.18 | $15.50 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 11 | 7 |
| Target Price | ★ $71.00 | $17.93 |
| AVG Volume (30 Days) | 1.4M | ★ 2.6M |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | N/A | ★ 18.11% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.97 |
| Revenue | $1,535,000.00 | ★ $1,578,000,000.00 |
| Revenue This Year | $425.31 | N/A |
| Revenue Next Year | $943.50 | N/A |
| P/E Ratio | ★ N/A | $15.92 |
| Revenue Growth | ★ 47.74 | N/A |
| 52 Week Low | $24.10 | $14.05 |
| 52 Week High | $60.34 | $24.10 |
Technical Indicators
Market Signals| Indicator | CRNX | FSK |
|---|---|---|
| Relative Strength Index (RSI) | 61.29 | 48.09 |
| Support Level | $44.52 | $15.06 |
| Resistance Level | $48.62 | $16.31 |
| Average True Range (ATR) | 2.00 | 0.32 |
| MACD | 0.29 | -0.02 |
| Stochastic Oscillator | 72.38 | 32.00 |
Price Performance
Historical ComparisonAbout CRNX Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant.
About FSK FS KKR Capital Corp.
FS KKR Capital Corp is an externally managed, non-diversified, closed-end management investment company that has elected to be regulated as a business development company. The company's investment objectives are to generate current income and, to a lesser extent, long-term capital appreciation. The company's portfolio is comprised of investments in senior secured loans and second lien secured loans of private middle market U.S. companies and, to a lesser extent, subordinated loans and certain asset-based financing loans of private U.S. companies.